Free Trial
→ Elon’s Terrifying Warning Forces Trump To Take Action (From American Hartford Gold) (Ad) Buy GDRX Stock  Free GDRX Stock Alerts

GoodRx (GDRX) Financials

GoodRx logo
$4.68 +0.04 (+0.86%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$4.72 +0.04 (+0.96%)
As of 05/2/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for GoodRx

Annual Income Statements for GoodRx

This table shows GoodRx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 14 66 -294 -25 -33 -8.87 16
Consolidated Net Income / (Loss)		 44 76 -294 -25 -33 -8.87 16
Net Income / (Loss) Continuing Operations		 44 76 -294 -25 -33 -8.87 16
Total Pre-Tax Income 		52 83 -303 -10 -23 -56 31
Total Operating Income		 77 140 -276 13 1.74 -27 66
Total Gross Profit		 243 374 521 699 701 683 744
Total Revenue		 250 388 551 745 767 750 792
Operating Revenue		 250 388 551 745 767 750 792
Total Cost of Revenue		 6.04 14 30 47 65 67 48
Operating Cost of Revenue		 6.04 14 30 47 65 67 48
Total Operating Expenses		 166 235 797 685 700 710 678
Selling, General & Admin Expense		 8.36 15 461 155 145 126 118
Marketing Expense		 104 177 255 370 358 341 367
Research & Development Expense		 44 29 62 126 143 136 124
Depreciation Expense		 9.81 14 18 35 54 108 70
Total Other Income / (Expense), net		 -25 -57 -28 -24 -25 -29 -34
Interest Expense		 25 54 28 24 34 57 55
Interest & Investment Income		 0.15 0.72 0.16 0.06 9.27 32 23
Other Income / (Expense), net		 -0.01 -2.97 -0.02 0.00 0.00 -4.01 -2.66
Income Tax Expense		 8.56 17 -9.83 15 9.60 -47 15
Basic Earnings per Share		 $0.12 $0.19 ($1.07) ($0.06) ($0.08) ($0.02) $0.04
Weighted Average Basic Shares Outstanding		 111.84M 226.61M 274.70M 409.98M 412.86M 410.32M 385.74M
Diluted Earnings per Share		 $0.12 $0.18 ($1.07) ($0.06) ($0.08) ($0.02) $0.04
Weighted Average Diluted Shares Outstanding		 118.34M 231.21M 274.70M 409.98M 412.86M 410.32M 392.17M
Weighted Average Basic & Diluted Shares Outstanding		 - - 392.13M 400.85M 397.57M 395.00M 383.61M

Quarterly Income Statements for GoodRx

This table shows GoodRx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -42 -1.97 -3.29 59 -38 -26 -1.01 6.69 3.97 6.74
Consolidated Net Income / (Loss)		 -42 -1.97 -3.29 59 -38 -26 -1.01 6.69 3.97 6.74
Net Income / (Loss) Continuing Operations		 -42 -1.97 -3.29 59 -38 -26 -1.01 6.69 3.97 6.74
Total Pre-Tax Income 		-22 -4.75 3.60 12 -47 -25 0.29 12 8.11 11
Total Operating Income		 -16 1.74 11 18 -38 -18 7.38 20 20 18
Total Gross Profit		 170 167 167 173 161 181 185 189 195 175
Total Revenue		 187 184 184 190 180 197 198 201 195 199
Operating Revenue		 187 184 184 190 180 197 198 201 195 199
Total Cost of Revenue		 17 17 17 16 19 15 12 12 0.00 24
Total Operating Expenses		 186 165 156 155 200 200 178 169 175 157
Selling, General & Admin Expense		 50 29 30 30 35 30 41 28 26 24
Marketing Expense		 86 84 79 77 92 94 90 93 90 94
Research & Development Expense		 36 37 33 31 40 32 31 31 30 32
Depreciation Expense		 14 16 15 16 33 44 16 17 18 19
Total Other Income / (Expense), net		 -6.56 -6.48 -7.71 -6.24 -8.27 -6.35 -7.09 -8.23 -12 -6.77
Interest Expense		 9.48 12 13 14 15 15 15 15 14 11
Interest & Investment Income		 2.92 5.45 7.23 7.81 8.65 8.47 7.56 6.33 4.80 4.59
Income Tax Expense		 19 -2.77 6.89 -47 -8.11 1.23 1.30 4.95 4.15 4.67
Basic Earnings per Share		 ($0.10) ($0.01) ($0.01) $0.14 ($0.09) ($0.06) $0.00 $0.02 $0.01 $0.01
Weighted Average Basic Shares Outstanding		 412.96M 412.86M 412.43M 412.22M 413.44M 410.32M 390.05M 376.25M 379.67M 385.74M
Diluted Earnings per Share		 ($0.10) ($0.01) ($0.01) $0.14 ($0.09) ($0.06) $0.00 $0.02 $0.01 $0.01
Weighted Average Diluted Shares Outstanding		 412.96M 412.86M 412.43M 414.34M 413.44M 410.32M 390.05M 384.73M 388.50M 392.17M
Weighted Average Basic & Diluted Shares Outstanding		 396.19M 397.57M 396.87M 397.85M 406.13M 395.00M 375.21M 379.45M 381.14M 383.61M

Annual Cash Flow Statements for GoodRx

This table details how cash moves in and out of GoodRx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 17 -19 946 -30 -184 -85 -224
Net Cash From Operating Activities		 45 83 131 179 147 138 184
Net Cash From Continuing Operating Activities		 45 73 131 179 147 138 184
Net Income / (Loss) Continuing Operations		 44 66 -294 -25 -33 -8.87 16
Consolidated Net Income / (Loss)		 44 66 -294 -25 -33 -8.87 16
Depreciation Expense		 9.81 14 18 35 54 108 70
Amortization Expense		 1.24 3.38 3.39 3.45 3.41 3.38 2.50
Non-Cash Adjustments To Reconcile Net Income		 4.62 -1.29 444 163 125 124 100
Changes in Operating Assets and Liabilities, net		 -14 -8.39 -41 3.46 -2.73 -87 -4.87
Net Cash From Investing Activities		 -3.46 -37 -92 -179 -210 -56 -70
Net Cash From Continuing Investing Activities		 -3.46 -37 -92 -179 -210 -56 -70
Purchase of Property, Plant & Equipment		 -3.46 -5.75 -36 -34 -55 -56 -70
Acquisitions		 0.00 -31 -56 -140 -157 0.00 0.00
Divestitures		 - - 0.00 0.00 17 0.00 0.00
Other Investing Activities, net		 - 0.00 0.00 -4.01 -15 0.00 0.00
Net Cash From Financing Activities		 -25 -55 906 -31 -120 -167 -337
Net Cash From Continuing Financing Activities		 -25 -55 906 -31 -120 -167 -337
Repayment of Debt		 -321 -214 -36 -7.03 -7.03 -5.27 -642
Repurchase of Common Equity		 0.00 0.00 -4.94 0.00 -102 -104 -159
Issuance of Debt		 902 155 28 - 0.00 0.00 472
Issuance of Common Equity		 0.00 1.62 992 0.00 0.00 1.39 1.77
Other Financing Activities, net		 3.35 3.04 -73 -23 -11 -60 -11
Cash Interest Paid		 19 48 25 20 31 49 55
Cash Income Taxes Paid		 12 19 29 -18 4.36 17 24

Quarterly Cash Flow Statements for GoodRx

This table details how cash moves in and out of GoodRx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -1.75 28 3.91 0.91 33 -123 -139 -8.39 -101 25
Net Cash From Operating Activities		 34 32 32 30 60 16 43 9.70 87 45
Net Cash From Continuing Operating Activities		 34 32 32 30 60 16 43 9.70 87 45
Net Income / (Loss) Continuing Operations		 -42 -1.97 -3.29 59 -38 -26 -1.01 6.69 3.97 6.74
Consolidated Net Income / (Loss)		 -42 -1.97 -3.29 59 -38 -26 -1.01 6.69 3.97 6.74
Depreciation Expense		 14 16 15 16 33 44 16 17 18 19
Amortization Expense		 0.85 0.85 0.85 0.85 0.84 0.84 0.84 0.83 0.41 0.42
Non-Cash Adjustments To Reconcile Net Income		 30 32 28 19 43 33 26 28 26 20
Changes in Operating Assets and Liabilities, net		 31 -14 -8.42 -65 21 -35 0.83 -42 39 -1.97
Net Cash From Investing Activities		 -14 1.29 -14 -15 -14 -13 -21 -17 -16 -17
Net Cash From Continuing Investing Activities		 -14 1.29 -14 -15 -14 -13 -21 -17 -16 -17
Purchase of Property, Plant & Equipment		 -14 -15 -14 -15 -14 -13 -21 -17 -16 -17
Net Cash From Financing Activities		 -22 -4.79 -14 -14 -14 -126 -161 -0.86 -172 -3.53
Net Cash From Continuing Financing Activities		 -22 -4.79 -14 -14 -14 -126 -161 -0.86 -172 -3.53
Repurchase of Common Equity		 -18 - -9.52 -8.92 -7.71 -78 -153 - -5.43 -0.19
Issuance of Common Equity		 - - - - - 0.74 - - - 0.91
Other Financing Activities, net		 -2.00 -3.03 -2.82 -3.97 -4.24 -49 -4.23 0.04 -2.29 -4.25

Annual Balance Sheets for GoodRx

This table presents GoodRx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 387 1,470 1,608 1,605 1,589 1,388
Total Current Assets		 87 1,086 1,089 920 873 659
Cash & Equivalents		 26 969 941 757 672 448
Accounts Receivable		 48 69 118 117 144 146
Prepaid Expenses		 12 46 30 45 57 65
Plant, Property, & Equipment, net		 1.86 23 22 20 16 13
Total Noncurrent Assets		 298 361 497 665 700 716
Goodwill		 236 261 330 412 411 411
Intangible Assets		 26 57 134 190 156 177
Noncurrent Deferred & Refundable Income Taxes		 2.21 13 - 0.00 65 77
Other Noncurrent Operating Assets		 33 30 34 63 68 51
Total Liabilities & Shareholders' Equity		 387 1,470 1,608 1,605 1,589 1,388
Total Liabilities		 737 759 776 790 827 663
Total Current Liabilities		 33 60 81 76 123 124
Short-Term Debt		 7.03 7.03 7.03 7.03 8.79 5.00
Accounts Payable		 7.85 10 18 18 36 14
Accrued Expenses		 16 38 51 48 71 99
Other Current Liabilities		 2.94 4.54 5.85 4.07 6.18 5.64
Total Noncurrent Liabilities		 704 699 695 713 704 540
Long-Term Debt		 664 660 656 652 648 487
Other Noncurrent Operating Liabilities		 40 39 39 62 57 53
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1,088 711 832 815 762 725
Total Preferred & Common Equity		 -1,088 711 832 815 762 725
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -1,088 711 832 815 762 725
Common Stock		 9.25 2,102 2,247 2,263 2,219 2,166
Retained Earnings		 -1,097 -1,390 -1,416 -1,449 -1,457 -1,441

Quarterly Balance Sheets for GoodRx

This table presents GoodRx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 1,567 1,612 1,692 1,708 1,454 1,475 1,355
Total Current Assets		 878 907 919 969 733 751 627
Cash & Equivalents		 729 761 762 795 533 525 424
Accounts Receivable		 121 116 123 121 145 162 131
Prepaid Expenses		 29 29 34 53 55 64 72
Plant, Property, & Equipment, net		 22 19 18 17 15 14 14
Total Noncurrent Assets		 666 686 755 722 706 710 714
Goodwill		 415 412 412 412 411 411 411
Intangible Assets		 197 197 202 181 162 168 174
Noncurrent Deferred & Refundable Income Taxes		 - - 63 58 65 65 66
Other Noncurrent Operating Assets		 54 76 78 71 68 67 64
Total Liabilities & Shareholders' Equity		 1,567 1,612 1,692 1,708 1,454 1,475 1,355
Total Liabilities		 779 784 797 827 823 806 658
Total Current Liabilities		 85 69 83 118 117 102 114
Short-Term Debt		 7.03 7.03 7.03 7.03 7.03 7.03 3.75
Accounts Payable		 11 12 6.80 33 34 17 12
Accrued Expenses		 61 48 66 75 71 73 93
Other Current Liabilities		 6.06 1.83 2.73 3.33 5.13 5.39 5.54
Total Noncurrent Liabilities		 694 715 714 709 706 704 544
Long-Term Debt		 653 651 650 649 647 646 488
Other Noncurrent Operating Liabilities		 40 64 64 60 60 58 56
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 788 827 895 881 631 669 696
Total Preferred & Common Equity		 788 827 895 881 631 669 696
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 788 827 895 881 631 669 696
Common Stock		 2,235 2,279 2,288 2,313 2,089 2,121 2,144
Retained Earnings		 -1,447 -1,452 -1,393 -1,432 -1,458 -1,452 -1,448

Annual Metrics and Ratios for GoodRx

This table displays calculated financial ratios and metrics derived from GoodRx's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 55.59% 41.85% 35.36% 2.83% -2.13% 5.61%
EBITDA Growth		 0.00% 74.05% -265.25% 120.24% 15.45% 34.90% 68.95%
EBIT Growth		 0.00% 76.98% -301.70% 104.86% -87.04% -1,884.52% 303.73%
NOPAT Growth		 0.00% 72.03% -273.60% 104.86% -87.04% -1,653.91% 281.46%
Net Income Growth		 0.00% 73.09% -487.36% 91.40% -29.99% 72.99% 284.82%
EPS Growth		 0.00% 50.00% -694.44% 94.39% -33.33% 75.00% 300.00%
Operating Cash Flow Growth		 0.00% 84.05% 57.70% 36.12% -17.90% -5.78% 32.97%
Free Cash Flow Firm Growth		 0.00% 0.00% -66.77% 55.01% -17.78% 69.98% 125.60%
Invested Capital Growth		 0.00% 0.00% 38.19% 36.09% 29.46% 4.14% 2.93%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 8.71% -3.66% 1.70% 0.25%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 119.32% -7.98% 5.31% 9.33%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 104.50% -85.22% -344.21% 136.49%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 104.50% -85.22% -286.81% 66.81%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 91.10% 53.61% -159.01% 201.05%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 93.94% 50.00% -166.67% 233.33%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -1.25% 24.31% -10.89% -10.38% 18.63%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -43.25% -76.28% 1,049.55%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -7.49% -0.41% 0.54% 0.53%
Profitability Metrics		 - - - - - - -
Gross Margin		 97.58% 96.39% 94.63% 93.73% 91.51% 91.08% 93.91%
EBITDA Margin		 35.38% 39.58% -46.11% 6.89% 7.74% 10.67% 17.07%
Operating Margin		 30.96% 35.98% -50.07% 1.80% 0.23% -3.60% 8.31%
EBIT Margin		 30.96% 35.21% -50.07% 1.80% 0.23% -4.13% 7.97%
Profit (Net Income) Margin		 17.55% 19.53% -53.32% -3.39% -4.28% -1.18% 2.07%
Tax Burden Percent		 83.66% 91.35% 96.76% 248.15% 141.31% 15.96% 52.10%
Interest Burden Percent		 67.77% 60.70% 110.05% -75.91% -1,336.65% 179.18% 49.79%
Effective Tax Rate		 16.34% 20.40% 0.00% 0.00% 0.00% 0.00% 47.90%
Return on Invested Capital (ROIC)		 0.00% 75.55% -55.07% 1.95% 0.19% -2.59% 4.53%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 64.58% -114.22% 13.84% 18.27% -20.17% -125.48%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -118.80% -107.70% -5.23% -4.18% 1.46% -2.33%
Return on Equity (ROE)		 0.00% -43.24% -162.77% -3.27% -3.99% -1.12% 2.21%
Cash Return on Invested Capital (CROIC)		 0.00% -124.45% -87.13% -28.62% -25.48% -6.64% 1.64%
Operating Return on Assets (OROA)		 0.00% 35.34% -29.70% 0.87% 0.11% -1.94% 4.25%
Return on Assets (ROA)		 0.00% 19.60% -31.62% -1.64% -2.04% -0.56% 1.10%
Return on Common Equity (ROCE)		 0.00% -134.16% 169.75% -3.27% -3.99% -1.12% 2.21%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -6.97% -41.28% -3.04% -4.03% -1.16% 2.26%
Net Operating Profit after Tax (NOPAT)		 65 111 -193 9.38 1.22 -19 34
NOPAT Margin		 25.90% 28.64% -35.05% 1.26% 0.16% -2.52% 4.33%
Net Nonoperating Expense Percent (NNEP)		 0.00% 10.97% 59.15% -11.88% -18.08% 17.59% 130.01%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 0.08% -1.33% 2.82%
Cost of Revenue to Revenue		 2.42% 3.61% 5.37% 6.27% 8.49% 8.92% 6.09%
SG&A Expenses to Revenue		 3.35% 3.78% 83.79% 20.75% 18.89% 16.73% 14.88%
R&D to Revenue		 17.59% 7.55% 11.23% 16.88% 18.67% 18.11% 15.62%
Operating Expenses to Revenue		 66.62% 60.41% 144.69% 91.93% 91.28% 94.68% 85.60%
Earnings before Interest and Taxes (EBIT)		 77 137 -276 13 1.74 -31 63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 88 154 -254 51 59 80 135
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 22.13 15.67 2.27 3.57 2.45
Price to Tangible Book Value (P/TBV)		 0.00 0.00 40.01 35.40 8.68 13.96 12.94
Price to Revenue (P/Rev)		 4.58 2.94 28.59 17.49 2.41 3.63 2.24
Price to Earnings (P/E)		 80.30 17.30 0.00 0.00 0.00 0.00 108.13
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.25% 5.78% 0.00% 0.00% 0.00% 0.00% 0.92%
Enterprise Value to Invested Capital (EV/IC)		 0.00 8.58 37.96 23.05 2.44 3.63 2.36
Enterprise Value to Revenue (EV/Rev)		 0.00 6.50 28.04 17.11 2.28 3.61 2.29
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 16.43 0.00 248.24 29.46 33.80 13.43
Enterprise Value to EBIT (EV/EBIT)		 0.00 18.46 0.00 951.60 1,005.70 0.00 28.74
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 22.70 0.00 1,359.43 1,436.71 0.00 52.93
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 30.31 117.55 71.36 11.91 19.56 9.87
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 146.03
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 -1.91 0.94 0.80 0.81 0.86 0.68
Long-Term Debt to Equity		 0.00 -1.89 0.93 0.79 0.80 0.85 0.67
Financial Leverage		 0.00 -1.84 0.94 -0.38 -0.23 -0.07 0.02
Leverage Ratio		 0.00 -1.10 5.15 1.99 1.95 2.03 2.00
Compound Leverage Factor		 0.00 -0.67 5.66 -1.51 -26.08 3.63 1.00
Debt to Total Capital		 0.00% 209.43% 48.39% 44.35% 44.71% 46.28% 40.42%
Short-Term Debt to Total Capital		 0.00% 2.19% 0.51% 0.47% 0.48% 0.62% 0.41%
Long-Term Debt to Total Capital		 0.00% 207.24% 47.88% 43.88% 44.23% 45.66% 40.01%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 230.06% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -339.50% 51.61% 55.65% 55.29% 53.72% 59.58%
Debt to EBITDA		 0.00 4.37 -2.63 12.90 11.10 8.20 3.64
Net Debt to EBITDA		 0.00 4.20 1.20 -5.41 -1.66 -0.20 0.32
Long-Term Debt to EBITDA		 0.00 4.32 -2.60 12.76 10.99 8.09 3.60
Debt to NOPAT		 0.00 6.03 -3.46 70.64 541.53 -34.73 14.33
Net Debt to NOPAT		 0.00 5.80 1.58 -29.65 -80.83 0.84 1.26
Long-Term Debt to NOPAT		 0.00 5.97 -3.42 69.89 535.75 -34.26 14.19
Altman Z-Score		 0.00 -0.71 11.72 10.09 1.25 1.66 1.33
Noncontrolling Interest Sharing Ratio		 0.00% -210.23% 204.29% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 2.59 18.24 13.42 12.05 7.12 5.32
Quick Ratio		 0.00 2.22 17.42 13.06 11.46 6.66 4.80
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -183 -305 -137 -162 -49 12
Operating Cash Flow to CapEx		 1,308.65% 1,448.70% 366.63% 518.85% 265.84% 247.99% 261.41%
Free Cash Flow to Firm to Interest Expense		 0.00 -3.36 -10.94 -5.81 -4.73 -0.86 0.23
Operating Cash Flow to Interest Expense		 1.81 1.53 4.71 7.56 4.29 2.44 3.34
Operating Cash Flow Less CapEx to Interest Expense		 1.67 1.42 3.42 6.10 2.67 1.45 2.06
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 1.00 0.59 0.48 0.48 0.47 0.53
Accounts Receivable Turnover		 0.00 8.07 9.43 7.98 6.52 5.75 5.47
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 208.72 44.20 33.38 37.00 41.97 55.42
Accounts Payable Turnover		 0.00 1.79 3.26 3.36 3.70 2.48 1.91
Days Sales Outstanding (DSO)		 0.00 45.25 38.73 45.74 56.00 63.43 66.69
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 204.45 111.90 108.57 98.71 147.16 190.78
Cash Conversion Cycle (CCC)		 0.00 -159.20 -73.18 -62.84 -42.71 -83.74 -124.09
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 294 407 553 716 746 768
Invested Capital Turnover		 0.00 2.64 1.57 1.55 1.21 1.03 1.05
Increase / (Decrease) in Invested Capital		 0.00 294 112 147 163 30 22
Enterprise Value (EV)		 0.00 2,524 15,439 12,757 1,748 2,705 1,816
Market Capitalization		 1,142 1,142 15,744 13,035 1,846 2,721 1,772
Book Value per Share		 $0.00 ($4.80) $1.82 $2.09 $2.06 $1.88 $1.90
Tangible Book Value per Share		 $0.00 ($5.96) $1.01 $0.92 $0.54 $0.48 $0.36
Total Capital		 0.00 320 1,378 1,495 1,474 1,418 1,216
Total Debt		 0.00 671 667 663 659 656 492
Total Long-Term Debt		 0.00 664 660 656 652 648 487
Net Debt		 0.00 645 -305 -278 -98 -16 43
Capital Expenditures (CapEx)		 3.46 5.75 36 34 55 56 70
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 34 62 74 93 87 92
Debt-free Net Working Capital (DFNWC)		 0.00 60 1,034 1,015 850 759 540
Net Working Capital (NWC)		 0.00 53 1,027 1,008 843 750 535
Net Nonoperating Expense (NNE)		 21 35 101 35 34 -10 18
Net Nonoperating Obligations (NNO)		 0.00 645 -305 -278 -98 -16 43
Total Depreciation and Amortization (D&A)		 11 17 22 38 58 111 72
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 8.81% 11.30% 9.88% 12.16% 11.56% 11.61%
Debt-free Net Working Capital to Revenue		 0.00% 15.52% 187.73% 136.13% 110.94% 101.17% 68.20%
Net Working Capital to Revenue		 0.00% 13.71% 186.46% 135.19% 110.02% 100.00% 67.57%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.07) ($0.06) ($0.08) ($0.02) $0.04
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 274.70M 409.98M 412.86M 410.32M 385.74M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.07) ($0.06) ($0.08) ($0.02) $0.04
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 274.70M 409.98M 412.86M 410.32M 392.17M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 392.13M 400.85M 397.57M 395.00M 383.61M
Normalized Net Operating Profit after Tax (NOPAT)		 65 111 -193 9.38 1.22 -19 34
Normalized NOPAT Margin		 25.90% 28.64% -35.05% 1.26% 0.16% -2.52% 4.33%
Pre Tax Income Margin		 20.98% 21.37% -55.10% -1.37% -3.03% -7.41% 3.97%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 3.08 2.51 -9.88 0.57 0.05 -0.55 1.15
NOPAT to Interest Expense		 2.58 2.04 -6.91 0.40 0.04 -0.33 0.62
EBIT Less CapEx to Interest Expense		 2.95 2.41 -11.16 -0.89 -1.56 -1.53 -0.13
NOPAT Less CapEx to Interest Expense		 2.44 1.94 -8.20 -1.06 -1.58 -1.32 -0.66
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 3,074.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 3,074.36% 0.00% -1.68% 0.00% -309.86% -1,172.46% 969.16%

Quarterly Metrics and Ratios for GoodRx

This table displays calculated financial ratios and metrics derived from GoodRx's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -3.99% -13.67% -9.51% -1.11% -3.93% 6.81% 7.55% 5.76% 8.50% 0.99%
EBITDA Growth		 -105.04% -22.10% -20.97% 248.12% -632.89% 44.38% -4.44% 6.86% 635.80% 44.09%
EBIT Growth		 -324.50% -85.22% -51.95% 552.38% -157.94% -1,152.85% -22.26% 8.58% 143.79% 199.41%
NOPAT Growth		 90.57% 101.52% -159.36% 3,248.10% -143.94% -1,152.85% -145.79% -87.19% 137.18% 183.90%
Net Income Growth		 -130.97% 95.06% -126.76% 4,254.49% 7.76% -1,211.82% 69.33% -88.61% 110.30% 126.05%
EPS Growth		 -150.00% 88.89% -133.33% 0.00% 10.00% -500.00% 100.00% -85.71% 111.11% 116.67%
Operating Cash Flow Growth		 -30.53% -36.00% 7.20% -41.50% 78.67% -50.22% 31.89% -67.52% 44.12% 181.97%
Free Cash Flow Firm Growth		 61.18% 28.63% 19.73% 130.21% 62.56% 73.76% 59.95% -90.66% 75.96% 73.79%
Invested Capital Growth		 20.26% 29.46% 20.11% 5.60% 3.15% 4.14% 3.77% 0.89% 2.95% 2.93%
Revenue Q/Q Growth		 -2.34% -1.71% -0.07% 3.09% -5.12% 9.27% 0.63% 1.38% -2.67% 1.71%
EBITDA Q/Q Growth		 -108.98% 2,093.51% 39.52% 39.43% -118.90% 492.72% -7.66% 55.91% -5.24% 5.61%
EBIT Q/Q Growth		 -288.26% 111.05% 446.63% 92.82% -321.38% 54.88% 140.36% 169.31% -10.72% 2.44%
NOPAT Q/Q Growth		 -288.26% 111.05% -950.50% 962.40% -130.09% 52.29% -98.55% 144.95% -12.70% 7.67%
Net Income Q/Q Growth		 -2,849.40% 95.27% -66.84% 1,886.81% -165.48% 32.80% 96.10% 763.43% -40.77% 69.99%
EPS Q/Q Growth		 0.00% 90.00% 0.00% 1,500.00% -164.29% 33.33% 100.00% 0.00% -50.00% 0.00%
Operating Cash Flow Q/Q Growth		 -33.92% -5.49% 1.28% -7.50% 101.80% -73.67% 168.38% -77.22% 795.39% -48.49%
Free Cash Flow Firm Q/Q Growth		 15.53% -22.41% 18.68% 135.93% -204.70% 14.20% -24.10% 108.38% -369.36% 6.46%
Invested Capital Q/Q Growth		 -3.85% -0.41% 1.08% 9.11% -6.08% 0.54% 0.71% 6.08% -4.16% 0.53%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 90.71% 90.57% 90.93% 91.39% 89.60% 92.29% 93.70% 94.08% 100.00% 87.98%
EBITDA Margin		 -0.49% 9.84% 13.74% 18.58% -3.70% 13.30% 12.21% 18.78% 18.28% 18.98%
Operating Margin		 -8.39% 0.94% 6.14% 9.65% -21.30% -9.30% 3.73% 9.91% 10.45% 9.15%
EBIT Margin		 -8.39% 0.94% 5.16% 9.65% -22.52% -9.30% 3.73% 9.91% 9.09% 9.15%
Profit (Net Income) Margin		 -22.28% -1.07% -1.79% 30.99% -21.39% -13.16% -0.51% 3.34% 2.03% 3.39%
Tax Burden Percent		 187.39% 41.56% -91.49% 487.12% 82.61% 105.01% -344.37% 57.48% 48.88% 59.08%
Interest Burden Percent		 141.74% -273.17% 37.87% 65.92% 114.98% 134.71% 3.97% 58.59% 45.71% 62.76%
Effective Tax Rate		 0.00% 0.00% 191.49% -387.12% 0.00% 0.00% 444.37% 42.52% 51.12% 40.92%
Return on Invested Capital (ROIC)		 -7.09% 0.80% -6.33% 45.54% -15.05% -6.68% -13.30% 5.56% 5.36% 5.66%
ROIC Less NNEP Spread (ROIC-NNEP)		 12.30% 2.49% -11.25% 80.30% -3.84% 16.22% 271.48% -36.37% 22.15% -23.37%
Return on Net Nonoperating Assets (RNNOA)		 -2.38% -0.57% 2.00% -8.20% 0.48% -1.17% 3.19% -0.52% -1.01% -0.43%
Return on Equity (ROE)		 -9.48% 0.23% -4.33% 37.35% -14.57% -7.85% -10.11% 5.04% 4.36% 5.23%
Cash Return on Invested Capital (CROIC)		 -17.14% -25.48% -18.98% -4.03% -3.77% -6.64% -6.63% -3.47% -0.17% 1.64%
Operating Return on Assets (OROA)		 -4.20% 0.45% 2.45% 4.38% -10.15% -4.37% 1.86% 4.85% 4.69% 4.87%
Return on Assets (ROA)		 -11.14% -0.51% -0.85% 14.06% -9.64% -6.18% -0.25% 1.63% 1.05% 1.81%
Return on Common Equity (ROCE)		 -9.48% 0.23% -4.33% 37.35% -14.57% -7.85% -10.11% 5.04% 4.36% 5.23%
Return on Equity Simple (ROE_SIMPLE)		 -8.98% 0.00% -5.85% 1.32% 1.71% 0.00% -1.04% -8.77% -2.33% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 1.22 -10 89 -27 -13 -25 11 9.97 11
NOPAT Margin		 -5.87% 0.66% -5.62% 47.02% -14.91% -6.51% -12.85% 5.70% 5.11% 5.41%
Net Nonoperating Expense Percent (NNEP)		 -19.39% -1.69% 4.92% -34.76% -11.21% -22.90% -284.78% 41.93% -16.79% 29.03%
Return On Investment Capital (ROIC_SIMPLE)		 - 0.08% - - - -0.90% - - - 0.88%
Cost of Revenue to Revenue		 9.29% 9.43% 9.07% 8.61% 10.40% 7.71% 6.30% 5.92% 0.00% 12.02%
SG&A Expenses to Revenue		 26.45% 15.52% 16.10% 15.93% 19.63% 15.44% 20.77% 13.75% 13.12% 11.86%
R&D to Revenue		 19.18% 19.97% 17.89% 16.49% 22.01% 16.29% 15.67% 15.38% 15.44% 15.98%
Operating Expenses to Revenue		 99.10% 89.63% 84.78% 81.73% 110.90% 101.59% 89.97% 84.17% 89.55% 78.82%
Earnings before Interest and Taxes (EBIT)		 -16 1.74 9.50 18 -41 -18 7.38 20 18 18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.91 18 25 35 -6.66 26 24 38 36 38
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.36 2.27 3.00 2.45 2.54 3.57 4.44 4.37 3.78 2.45
Price to Tangible Book Value (P/TBV)		 10.57 8.68 11.40 7.79 7.78 13.96 48.19 32.22 23.57 12.94
Price to Revenue (P/Rev)		 2.34 2.41 3.33 2.94 3.04 3.63 3.67 3.78 3.33 2.24
Price to Earnings (P/E)		 0.00 0.00 0.00 185.81 149.04 0.00 0.00 0.00 0.00 108.13
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.54% 0.67% 0.00% 0.00% 0.00% 0.00% 0.92%
Enterprise Value to Invested Capital (EV/IC)		 2.49 2.44 3.29 2.64 2.83 3.63 3.89 3.83 3.54 2.36
Enterprise Value to Revenue (EV/Rev)		 2.25 2.28 3.19 2.80 2.85 3.61 3.83 3.94 3.42 2.29
Enterprise Value to EBITDA (EV/EBITDA)		 27.77 29.46 43.75 26.22 27.64 33.80 37.07 37.56 21.84 13.43
Enterprise Value to EBIT (EV/EBIT)		 152.28 1,005.70 0.00 133.39 0.00 0.00 0.00 0.00 101.09 28.74
Enterprise Value to NOPAT (EV/NOPAT)		 217.54 1,436.71 0.00 190.55 0.00 0.00 0.00 0.00 131.34 52.93
Enterprise Value to Operating Cash Flow (EV/OCF)		 10.87 11.91 15.99 16.32 13.61 19.56 19.68 23.78 17.42 9.87
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 146.03
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.84 0.81 0.80 0.73 0.74 0.86 1.04 0.98 0.71 0.68
Long-Term Debt to Equity		 0.83 0.80 0.79 0.73 0.74 0.85 1.02 0.96 0.70 0.67
Financial Leverage		 -0.19 -0.23 -0.18 -0.10 -0.12 -0.07 0.01 0.01 -0.05 0.02
Leverage Ratio		 1.95 1.95 1.95 1.92 1.96 2.03 2.10 2.02 1.94 2.00
Compound Leverage Factor		 2.76 -5.33 0.74 1.26 2.26 2.73 0.08 1.19 0.89 1.26
Debt to Total Capital		 45.56% 44.71% 44.29% 42.31% 42.66% 46.28% 50.88% 49.37% 41.37% 40.42%
Short-Term Debt to Total Capital		 0.49% 0.48% 0.47% 0.45% 0.46% 0.62% 0.55% 0.53% 0.32% 0.41%
Long-Term Debt to Total Capital		 45.08% 44.23% 43.82% 41.86% 42.21% 45.66% 50.33% 48.84% 41.05% 40.01%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 54.44% 55.29% 55.71% 57.69% 57.34% 53.72% 49.12% 50.63% 58.63% 59.58%
Debt to EBITDA		 10.23 11.10 12.09 8.26 8.63 8.20 8.28 8.03 3.97 3.64
Net Debt to EBITDA		 -1.07 -1.66 -1.90 -1.32 -1.83 -0.20 1.53 1.57 0.55 0.32
Long-Term Debt to EBITDA		 10.13 10.99 11.96 8.17 8.54 8.09 8.19 7.94 3.94 3.60
Debt to NOPAT		 80.18 541.53 -139.84 60.01 -134.17 -34.73 -30.19 -31.76 23.89 14.33
Net Debt to NOPAT		 -8.38 -80.83 21.95 -9.61 28.47 0.84 -5.56 -6.22 3.29 1.26
Long-Term Debt to NOPAT		 79.32 535.75 -138.35 59.37 -132.74 -34.26 -29.87 -31.42 23.71 14.19
Altman Z-Score		 1.22 1.25 1.75 1.57 1.40 1.69 1.69 1.90 1.98 1.23
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 10.34 12.05 13.15 11.14 8.23 7.12 6.29 7.32 5.48 5.32
Quick Ratio		 10.00 11.46 12.72 10.72 7.77 6.66 5.82 6.70 4.85 4.80
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -132 -162 -132 47 -49 -42 -53 4.42 -12 -11
Operating Cash Flow to CapEx		 244.88% 208.50% 225.98% 199.65% 441.64% 123.28% 206.58% 56.31% 547.71% 268.82%
Free Cash Flow to Firm to Interest Expense		 -13.95 -13.57 -10.02 3.36 -3.36 -2.87 -3.60 0.30 -0.82 -0.98
Operating Cash Flow to Interest Expense		 3.56 2.67 2.46 2.13 4.09 1.07 2.91 0.67 6.02 3.94
Operating Cash Flow Less CapEx to Interest Expense		 2.11 1.39 1.37 1.06 3.17 0.20 1.50 -0.52 4.92 2.47
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.50 0.48 0.47 0.45 0.45 0.47 0.50 0.49 0.52 0.53
Accounts Receivable Turnover		 7.25 6.52 6.23 6.05 6.10 5.75 5.85 5.44 6.27 5.47
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 36.07 37.00 36.16 36.52 37.67 41.97 44.81 47.82 51.82 55.42
Accounts Payable Turnover		 4.38 3.70 5.51 5.74 3.16 2.48 2.73 4.92 1.74 1.91
Days Sales Outstanding (DSO)		 50.32 56.00 58.55 60.32 59.87 63.43 62.38 67.14 58.18 66.69
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 83.29 98.71 66.20 63.59 115.55 147.16 133.63 74.21 209.24 190.78
Cash Conversion Cycle (CCC)		 -32.97 -42.71 -7.65 -3.27 -55.68 -83.74 -71.24 -7.07 -151.06 -124.09
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 719 716 724 790 742 746 751 797 764 768
Invested Capital Turnover		 1.21 1.21 1.13 0.97 1.01 1.03 1.04 0.98 1.05 1.05
Increase / (Decrease) in Invested Capital		 121 163 121 42 23 30 27 7.01 22 22
Enterprise Value (EV)		 1,790 1,748 2,382 2,086 2,101 2,705 2,925 3,054 2,701 1,816
Market Capitalization		 1,859 1,846 2,485 2,191 2,240 2,721 2,804 2,927 2,633 1,772
Book Value per Share		 $1.98 $2.06 $2.08 $2.26 $2.22 $1.88 $1.60 $1.78 $1.84 $1.90
Tangible Book Value per Share		 $0.44 $0.54 $0.55 $0.71 $0.72 $0.48 $0.15 $0.24 $0.29 $0.36
Total Capital		 1,448 1,474 1,485 1,552 1,537 1,418 1,285 1,322 1,188 1,216
Total Debt		 660 659 658 657 656 656 654 653 491 492
Total Long-Term Debt		 653 652 651 650 649 648 647 646 488 487
Net Debt		 -69 -98 -103 -105 -139 -16 120 128 68 43
Capital Expenditures (CapEx)		 14 15 14 15 14 13 21 17 16 17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 72 93 84 82 63 87 90 130 92 92
Debt-free Net Working Capital (DFNWC)		 800 850 845 844 858 759 623 655 516 540
Net Working Capital (NWC)		 793 843 838 837 851 750 616 648 512 535
Net Nonoperating Expense (NNE)		 31 3.19 -7.05 30 12 13 -24 4.73 6.01 4.00
Net Nonoperating Obligations (NNO)		 -69 -98 -103 -105 -139 -16 120 128 68 43
Total Depreciation and Amortization (D&A)		 15 16 16 17 34 44 17 18 18 20
Debt-free, Cash-free Net Working Capital to Revenue		 9.01% 12.16% 11.24% 10.97% 8.59% 11.56% 11.78% 16.80% 11.69% 11.61%
Debt-free Net Working Capital to Revenue		 100.60% 110.94% 113.10% 113.24% 116.34% 101.17% 81.57% 84.52% 65.31% 68.20%
Net Working Capital to Revenue		 99.71% 110.02% 112.16% 112.30% 115.39% 100.00% 80.65% 83.61% 64.83% 67.57%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.10) ($0.01) ($0.01) $0.14 ($0.09) ($0.06) $0.00 $0.02 $0.01 $0.01
Adjusted Weighted Average Basic Shares Outstanding		 412.96M 412.86M 412.43M 412.22M 413.44M 410.32M 390.05M 376.25M 379.67M 385.74M
Adjusted Diluted Earnings per Share		 ($0.10) ($0.01) ($0.01) $0.14 ($0.09) ($0.06) $0.00 $0.02 $0.01 $0.01
Adjusted Weighted Average Diluted Shares Outstanding		 412.96M 412.86M 412.43M 414.34M 413.44M 410.32M 390.05M 384.73M 388.50M 392.17M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 396.19M 397.57M 396.87M 397.85M 406.13M 395.00M 375.21M 379.45M 381.14M 383.61M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 1.22 7.91 13 -27 -13 5.17 11 14 11
Normalized NOPAT Margin		 -5.87% 0.66% 4.30% 6.76% -14.91% -6.51% 2.61% 5.70% 7.32% 5.41%
Pre Tax Income Margin		 -11.89% -2.58% 1.95% 6.36% -25.90% -12.53% 0.15% 5.81% 4.15% 5.75%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -1.66 0.15 0.72 1.30 -2.75 -1.23 0.50 1.36 1.23 1.60
NOPAT to Interest Expense		 -1.16 0.10 -0.79 6.35 -1.82 -0.86 -1.74 0.78 0.69 0.95
EBIT Less CapEx to Interest Expense		 -3.11 -1.14 -0.37 0.24 -3.68 -2.10 -0.90 0.18 0.13 0.14
NOPAT Less CapEx to Interest Expense		 -2.61 -1.18 -1.88 5.28 -2.75 -1.73 -3.14 -0.40 -0.41 -0.52
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -143.73% -309.86% -56.75% 308.68% 173.99% -1,172.46% -3,760.18% -406.90% -1,458.06% 969.16%

Frequently Asked Questions About GoodRx's Financials

When does GoodRx's financial year end?

According to the most recent income statement we have on file, GoodRx's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has GoodRx's net income changed over the last 6 years?

In the past 6 years, GoodRx's net income has ranged from -$293.62 million in 2020 to $75.80 million in 2019, and is currently $16.39 million as of their latest financial filing in 2024. Check out GoodRx's forecast to explore projected trends and price targets.

What is GoodRx's operating income?
GoodRx's total operating income in 2024 was $65.85 million, based on the following breakdown:
  • Total Gross Profit: $744.11 million
  • Total Operating Expenses: $678.26 million
How has GoodRx revenue changed over the last 6 years?

Over the last 6 years, GoodRx's total revenue changed from $249.52 million in 2018 to $792.32 million in 2024, a change of 217.5%.

How much debt does GoodRx have?

GoodRx's total liabilities were at $663.41 million at the end of 2024, a 19.8% decrease from 2023, and a 10.0% decrease since 2019.

How much cash does GoodRx have?

In the past 5 years, GoodRx's cash and equivalents has ranged from $26.05 million in 2019 to $968.69 million in 2020, and is currently $448.35 million as of their latest financial filing in 2024.

How has GoodRx's book value per share changed over the last 6 years?

Over the last 6 years, GoodRx's book value per share changed from 0.00 in 2018 to 1.90 in 2024, a change of 190.1%.


Related Companies

This page (NASDAQ:GDRX) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...
Stansberry Research | Sponsored
How to invest in Elon Musk’s Optimus before its launch
Elon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...
InvestorPlace | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored